Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 3/20 | 0.59 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 3/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14358480 | 1.00 | MMP13 (0.59) | MMP13HSD17B3ALDH1A1MAPTKMT2A | |
| SCHEMBL8738834 | 0.90 | MAPT (0.58) | ALDH1A1MAPTKMT2AMEN1KDM4E | |
| SCHEMBL14358738 | 0.88 | ALDH1A1 (0.60) | ALDH1A1MAPTKMT2AMEN1KDM4E | |
| SCHEMBL14358741 | 0.88 | ALDH1A1 (0.60) | ALDH1A1MAPTKMT2AMEN1KDM4E | |
| SCHEMBL14358669 | 0.82 | MAPT (0.60) | MMP13HSD17B3ALDH1A1MAPTKMT2A | |
| SCHEMBL14358667 | 0.82 | MAPT (0.60) | MMP13HSD17B3ALDH1A1MAPTKMT2A | |
| SCHEMBL14359082 | 0.82 | MAPT (0.50) | MMP13HSD17B3ALDH1A1MAPTKMT2A | |
| SCHEMBL14359085 | 0.82 | MAPT (0.50) | MMP13HSD17B3ALDH1A1MAPTKMT2A | |
| SCHEMBL14358579 | 0.79 | NOX1 (0.54) | MMP13HSD17B3ALDH1A1MAPTKMT2A | |
| SCHEMBL14358580 | 0.79 | NOX1 (0.54) | MMP13HSD17B3ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2724156-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | The Jackson Laboratory (US) | 2014-04-30 | — | — | EP | claimed |
| CN-103765212-A | Methods and compositions for treating cancer and autoimmune diseases | JACKSON LAB | 2014-04-30 | — | — | CN | claimed |
| US-20130184342-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | THE JACKSON LABORATORY (US) | 2013-07-18 | — | — | US | claimed |
| WO-2013003112-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | THE JACKSON LABORATORY (US) | 2013-01-03 | — | — | WO | claimed |
| US-10207988-B2 | Methods and compositions for treatment of cancer and autoimmune disease | THE JACKSON LABORATORY (US) | 2019-02-19 | — | — | US | disclosed |
| EP-2724156-B1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | JACKSON LAB (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-2724156-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | The Jackson Laboratory (US) | 2014-04-30 | — | — | EP | disclosed |
| CN-103765212-A | Methods and compositions for treating cancer and autoimmune diseases | JACKSON LAB | 2014-04-30 | — | — | CN | disclosed |
| US-20130184342-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | THE JACKSON LABORATORY (US) | 2013-07-18 | — | — | US | disclosed |
| WO-2013003112-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | THE JACKSON LABORATORY (US) | 2013-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184342-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | BAK1, SSB, MRE11 | MMP13 1762/4885HSD17B3 2702/4885ALDH1A1 3148/4885 |
| US-10207988-B2 | Methods and compositions for treatment of cancer and autoimmune disease | BAK1, SSB, MRE11 | MMP13 1762/4885HSD17B3 2702/4885ALDH1A1 3148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.